

Global Mepolizumab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/GAEA90BCE724EN.html>

Date: June 2026

Pages: 73

Price: US\$ 3,480.00 (Single User License)

ID: GAEA90BCE724EN

Abstracts

According to our (Global Info Research) latest study, the global Mepolizumab market size was valued at US\$ 2732 million in 2025 and is forecast to a readjusted size of US\$ 7259 million by 2032 with a CAGR of 16.3% during review period.

Mepolizumab is a humanized anti-interleukin-5 (IL-5) monoclonal antibody drug. It specifically targets and binds to the IL-5 cytokine, blocks its combination with receptors on the surface of eosinophils, and inhibits the activation, proliferation and survival of eosinophils, thereby reducing eosinophilic inflammatory responses in the respiratory tract and the whole body. It is mainly applied in the treatment of inflammatory diseases such as eosinophilic asthma and chronic rhinosinusitis with nasal polyps. With stable clinical efficacy and favorable safety, it can effectively reduce the risk of severe exacerbations and provide a long-acting targeted treatment option for eosinophil-related respiratory diseases. In 2025, global Mepolizumab (Nucala) production reached approximately 1.71 million vials.

Mepolizumab, the world's first approved anti-IL-5 monoclonal antibody, targets eosinophil-related diseases mediated by interleukin-5. It has built a diversified product portfolio centered on severe asthma, with gradually expanded indications including chronic rhinosinusitis with nasal polyps and eosinophilic granulomatosis with polyangiitis. Its market development is driven by the popularization of precision diagnosis and treatment as well as the general shift toward biological agents. Global regulatory authorities continue to expand its applicable populations and age ranges, meanwhile promoting its penetration from hospital settings to outpatient and home care scenarios. In terms of competition, GSK occupies a leading position, continuously optimizing its indication spectrum through clinical research and developing next-generation long-acting formulations to improve patient compliance and market

competitiveness. Regional market growth benefits from improved medical infrastructure and rising awareness of rare and refractory inflammatory diseases, with emerging markets such as the Asia-Pacific region showing great growth potential. Overall, key market drivers include improved diagnostic capabilities, greater accessibility of biological drugs, and optimized long-term treatment costs. Major challenges involve difficulties in target patient screening, inconsistent reimbursement policies, and competition from similar therapeutic drugs. The overall industry development is characterized by indication expansion, regional market penetration and continuous product iteration.

This report is a detailed and comprehensive analysis for global Mepolizumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Mepolizumab market size and forecasts, in consumption value (\$ Million), sales quantity (Units), and average selling prices (US\$/Unit), 2021-2032

Global Mepolizumab market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (Units), and average selling prices (US\$/Unit), 2021-2032

Global Mepolizumab market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (Units), and average selling prices (US\$/Unit), 2021-2032

Global Mepolizumab market shares of main players, shipments in revenue (\$ Million), sales quantity (Units), and ASP (US\$/Unit), 2021-2026

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Mepolizumab

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Mepolizumab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, GlaxoSmithKline, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Mepolizumab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

100mg Pre-filled Syringe

100mg Lyophilized Powder for Injection

Market segment by Combination Therapy

Combination of Mepolizumab and Inhaled Corticosteroids

Combination of Mepolizumab and LABA

Market segment by Route of Administration

Subcutaneous Injection

Subcutaneous Infusion

Market segment by Sales Channel

Hospital

Retail

Online

Market segment by Application

Severe Eosinophilic Asthma

Chronic Rhinosinusitis With Nasal Polyps

Eosinophilic Granulomatosis With Polyangiitis

Others

Major players covered

GSK, GlaxoSmithKline

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of

Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Mepolizumab product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Mepolizumab, with price, sales quantity, revenue, and global market share of Mepolizumab from 2021 to 2026.

Chapter 3, the Mepolizumab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Mepolizumab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026. and Mepolizumab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Mepolizumab.

Chapter 14 and 15, to describe Mepolizumab sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Market Analysis by Type

1.3.1 Overview: Global Mepolizumab Consumption Value by Type: 2021 Versus 2025 Versus 2032

1.3.2 100mg Pre-filled Syringe

1.3.3 100mg Lyophilized Powder for Injection

1.4 Market Analysis by Combination Therapy

1.4.1 Overview: Global Mepolizumab Consumption Value by Combination Therapy: 2021 Versus 2025 Versus 2032

1.4.2 Combination of Mepolizumab and Inhaled Corticosteroids

1.4.3 Combination of Mepolizumab and LABA

1.5 Market Analysis by Route of Administration

1.5.1 Overview: Global Mepolizumab Consumption Value by Route of Administration: 2021 Versus 2025 Versus 2032

1.5.2 Subcutaneous Injection

1.5.3 Subcutaneous Infusion

1.6 Market Analysis by Sales Channel

1.6.1 Overview: Global Mepolizumab Consumption Value by Sales Channel: 2021 Versus 2025 Versus 2032

1.6.2 Hospital

1.6.3 Retail

1.6.4 Online

1.7 Market Analysis by Application

1.7.1 Overview: Global Mepolizumab Consumption Value by Application: 2021 Versus 2025 Versus 2032

1.7.2 Severe Eosinophilic Asthma

1.7.3 Chronic Rhinosinusitis With Nasal Polyps

1.7.4 Eosinophilic Granulomatosis With Polyangiitis

1.7.5 Others

1.8 Global Mepolizumab Market Size & Forecast

1.8.1 Global Mepolizumab Consumption Value (2021 & 2025 & 2032)

1.8.2 Global Mepolizumab Sales Quantity (2021-2032)

1.8.3 Global Mepolizumab Average Price (2021-2032)

2 MANUFACTURERS PROFILES

2.1 GSK, GlaxoSmithKline

2.1.1 GSK, GlaxoSmithKline Details

2.1.2 GSK, GlaxoSmithKline Major Business

2.1.3 GSK, GlaxoSmithKline Mepolizumab Product and Services

2.1.4 GSK, GlaxoSmithKline Mepolizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)

2.1.5 GSK, GlaxoSmithKline Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: MEPOLIZUMAB BY MANUFACTURER

3.1 Global Mepolizumab Sales Quantity by Manufacturer (2021-2026)

3.2 Global Mepolizumab Revenue by Manufacturer (2021-2026)

3.3 Global Mepolizumab Average Price by Manufacturer (2021-2026)

3.4 Market Share Analysis (2025)

3.4.1 Producer Shipments of Mepolizumab by Manufacturer Revenue (\$MM) and Market Share (%): 2025

3.4.2 Top 3 Mepolizumab Manufacturer Market Share in 2025

3.4.3 Top 6 Mepolizumab Manufacturer Market Share in 2025

3.5 Mepolizumab Market: Overall Company Footprint Analysis

3.5.1 Mepolizumab Market: Region Footprint

3.5.2 Mepolizumab Market: Company Product Type Footprint

3.5.3 Mepolizumab Market: Company Product Application Footprint

3.6 New Market Entrants and Barriers to Market Entry

3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

4.1 Global Mepolizumab Market Size by Region

4.1.1 Global Mepolizumab Sales Quantity by Region (2021-2032)

4.1.2 Global Mepolizumab Consumption Value by Region (2021-2032)

4.1.3 Global Mepolizumab Average Price by Region (2021-2032)

4.2 North America Mepolizumab Consumption Value (2021-2032)

4.3 Europe Mepolizumab Consumption Value (2021-2032)

4.4 Asia-Pacific Mepolizumab Consumption Value (2021-2032)

4.5 South America Mepolizumab Consumption Value (2021-2032)

4.6 Middle East & Africa Mepolizumab Consumption Value (2021-2032)

5 MARKET SEGMENT BY TYPE

- 5.1 Global Mepolizumab Sales Quantity by Type (2021-2032)
- 5.2 Global Mepolizumab Consumption Value by Type (2021-2032)
- 5.3 Global Mepolizumab Average Price by Type (2021-2032)

6 MARKET SEGMENT BY APPLICATION

- 6.1 Global Mepolizumab Sales Quantity by Application (2021-2032)
- 6.2 Global Mepolizumab Consumption Value by Application (2021-2032)
- 6.3 Global Mepolizumab Average Price by Application (2021-2032)

7 NORTH AMERICA

- 7.1 North America Mepolizumab Sales Quantity by Type (2021-2032)
- 7.2 North America Mepolizumab Sales Quantity by Application (2021-2032)
- 7.3 North America Mepolizumab Market Size by Country
 - 7.3.1 North America Mepolizumab Sales Quantity by Country (2021-2032)
 - 7.3.2 North America Mepolizumab Consumption Value by Country (2021-2032)
 - 7.3.3 United States Market Size and Forecast (2021-2032)
 - 7.3.4 Canada Market Size and Forecast (2021-2032)
 - 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 EUROPE

- 8.1 Europe Mepolizumab Sales Quantity by Type (2021-2032)
- 8.2 Europe Mepolizumab Sales Quantity by Application (2021-2032)
- 8.3 Europe Mepolizumab Market Size by Country
 - 8.3.1 Europe Mepolizumab Sales Quantity by Country (2021-2032)
 - 8.3.2 Europe Mepolizumab Consumption Value by Country (2021-2032)
 - 8.3.3 Germany Market Size and Forecast (2021-2032)
 - 8.3.4 France Market Size and Forecast (2021-2032)
 - 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
 - 8.3.6 Russia Market Size and Forecast (2021-2032)
 - 8.3.7 Italy Market Size and Forecast (2021-2032)

9 ASIA-PACIFIC

- 9.1 Asia-Pacific Mepolizumab Sales Quantity by Type (2021-2032)

- 9.2 Asia-Pacific Mepolizumab Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Mepolizumab Market Size by Region
 - 9.3.1 Asia-Pacific Mepolizumab Sales Quantity by Region (2021-2032)
 - 9.3.2 Asia-Pacific Mepolizumab Consumption Value by Region (2021-2032)
 - 9.3.3 China Market Size and Forecast (2021-2032)
 - 9.3.4 Japan Market Size and Forecast (2021-2032)
 - 9.3.5 South Korea Market Size and Forecast (2021-2032)
 - 9.3.6 India Market Size and Forecast (2021-2032)
 - 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
 - 9.3.8 Australia Market Size and Forecast (2021-2032)

10 SOUTH AMERICA

- 10.1 South America Mepolizumab Sales Quantity by Type (2021-2032)
- 10.2 South America Mepolizumab Sales Quantity by Application (2021-2032)
- 10.3 South America Mepolizumab Market Size by Country
 - 10.3.1 South America Mepolizumab Sales Quantity by Country (2021-2032)
 - 10.3.2 South America Mepolizumab Consumption Value by Country (2021-2032)
 - 10.3.3 Brazil Market Size and Forecast (2021-2032)
 - 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 MIDDLE EAST & AFRICA

- 11.1 Middle East & Africa Mepolizumab Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Mepolizumab Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Mepolizumab Market Size by Country
 - 11.3.1 Middle East & Africa Mepolizumab Sales Quantity by Country (2021-2032)
 - 11.3.2 Middle East & Africa Mepolizumab Consumption Value by Country (2021-2032)
 - 11.3.3 Turkey Market Size and Forecast (2021-2032)
 - 11.3.4 Egypt Market Size and Forecast (2021-2032)
 - 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
 - 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 MARKET DYNAMICS

- 12.1 Mepolizumab Market Drivers
- 12.2 Mepolizumab Market Restraints
- 12.3 Mepolizumab Trends Analysis
- 12.4 Porters Five Forces Analysis

- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 RAW MATERIAL AND INDUSTRY CHAIN

- 13.1 Raw Material of Mepolizumab and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Mepolizumab
- 13.3 Mepolizumab Production Process
- 13.4 Industry Value Chain Analysis

14 SHIPMENTS BY DISTRIBUTION CHANNEL

- 14.1 Sales Channel
 - 14.1.1 Direct to End-User
 - 14.1.2 Distributors
- 14.2 Mepolizumab Typical Distributors
- 14.3 Mepolizumab Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

- 16.1 Methodology
- 16.2 Research Process and Data Source
- 16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Mepolizumab Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Table 2. Global Mepolizumab Consumption Value by Combination Therapy, (USD Million), 2021 & 2025 & 2032

Table 3. Global Mepolizumab Consumption Value by Route of Administration, (USD Million), 2021 & 2025 & 2032

Table 4. Global Mepolizumab Consumption Value by Sales Channel, (USD Million), 2021 & 2025 & 2032

Table 5. Global Mepolizumab Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 6. GSK, GlaxoSmithKline Basic Information, Manufacturing Base and Competitors

Table 7. GSK, GlaxoSmithKline Major Business

Table 8. GSK, GlaxoSmithKline Mepolizumab Product and Services

Table 9. GSK, GlaxoSmithKline Mepolizumab Sales Quantity (Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 10. GSK, GlaxoSmithKline Recent Developments/Updates

Table 11. Global Mepolizumab Sales Quantity by Manufacturer (2021-2026) & (Units)

Table 12. Global Mepolizumab Revenue by Manufacturer (2021-2026) & (USD Million)

Table 13. Global Mepolizumab Average Price by Manufacturer (2021-2026) & (US\$/Unit)

Table 14. Market Position of Manufacturers in Mepolizumab, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025

Table 15. Head Office and Mepolizumab Production Site of Key Manufacturer

Table 16. Mepolizumab Market: Company Product Type Footprint

Table 17. Mepolizumab Market: Company Product Application Footprint

Table 18. Mepolizumab New Market Entrants and Barriers to Market Entry

Table 19. Mepolizumab Mergers, Acquisition, Agreements, and Collaborations

Table 20. Global Mepolizumab Consumption Value by Region (2021-2025-2032) & (USD Million) & CAGR

Table 21. Global Mepolizumab Sales Quantity by Region (2021-2026) & (Units)

Table 22. Global Mepolizumab Sales Quantity by Region (2027-2032) & (Units)

Table 23. Global Mepolizumab Consumption Value by Region (2021-2026) & (USD Million)

Table 24. Global Mepolizumab Consumption Value by Region (2027-2032) & (USD

Million)

Table 25. Global Mepolizumab Average Price by Region (2021-2026) & (US\$/Unit)

Table 26. Global Mepolizumab Average Price by Region (2027-2032) & (US\$/Unit)

Table 27. Global Mepolizumab Sales Quantity by Type (2021-2026) & (Units)

Table 28. Global Mepolizumab Sales Quantity by Type (2027-2032) & (Units)

Table 29. Global Mepolizumab Consumption Value by Type (2021-2026) & (USD Million)

Table 30. Global Mepolizumab Consumption Value by Type (2027-2032) & (USD Million)

Table 31. Global Mepolizumab Average Price by Type (2021-2026) & (US\$/Unit)

Table 32. Global Mepolizumab Average Price by Type (2027-2032) & (US\$/Unit)

Table 33. Global Mepolizumab Sales Quantity by Application (2021-2026) & (Units)

Table 34. Global Mepolizumab Sales Quantity by Application (2027-2032) & (Units)

Table 35. Global Mepolizumab Consumption Value by Application (2021-2026) & (USD Million)

Table 36. Global Mepolizumab Consumption Value by Application (2027-2032) & (USD Million)

Table 37. Global Mepolizumab Average Price by Application (2021-2026) & (US\$/Unit)

Table 38. Global Mepolizumab Average Price by Application (2027-2032) & (US\$/Unit)

Table 39. North America Mepolizumab Sales Quantity by Type (2021-2026) & (Units)

Table 40. North America Mepolizumab Sales Quantity by Type (2027-2032) & (Units)

Table 41. North America Mepolizumab Sales Quantity by Application (2021-2026) & (Units)

Table 42. North America Mepolizumab Sales Quantity by Application (2027-2032) & (Units)

Table 43. North America Mepolizumab Sales Quantity by Country (2021-2026) & (Units)

Table 44. North America Mepolizumab Sales Quantity by Country (2027-2032) & (Units)

Table 45. North America Mepolizumab Consumption Value by Country (2021-2026) & (USD Million)

Table 46. North America Mepolizumab Consumption Value by Country (2027-2032) & (USD Million)

Table 47. Europe Mepolizumab Sales Quantity by Type (2021-2026) & (Units)

Table 48. Europe Mepolizumab Sales Quantity by Type (2027-2032) & (Units)

Table 49. Europe Mepolizumab Sales Quantity by Application (2021-2026) & (Units)

Table 50. Europe Mepolizumab Sales Quantity by Application (2027-2032) & (Units)

Table 51. Europe Mepolizumab Sales Quantity by Country (2021-2026) & (Units)

Table 52. Europe Mepolizumab Sales Quantity by Country (2027-2032) & (Units)

Table 53. Europe Mepolizumab Consumption Value by Country (2021-2026) & (USD Million)

Table 54. Europe Mepolizumab Consumption Value by Country (2027-2032) & (USD Million)

Table 55. Asia-Pacific Mepolizumab Sales Quantity by Type (2021-2026) & (Units)

Table 56. Asia-Pacific Mepolizumab Sales Quantity by Type (2027-2032) & (Units)

Table 57. Asia-Pacific Mepolizumab Sales Quantity by Application (2021-2026) & (Units)

Table 58. Asia-Pacific Mepolizumab Sales Quantity by Application (2027-2032) & (Units)

Table 59. Asia-Pacific Mepolizumab Sales Quantity by Region (2021-2026) & (Units)

Table 60. Asia-Pacific Mepolizumab Sales Quantity by Region (2027-2032) & (Units)

Table 61. Asia-Pacific Mepolizumab Consumption Value by Region (2021-2026) & (USD Million)

Table 62. Asia-Pacific Mepolizumab Consumption Value by Region (2027-2032) & (USD Million)

Table 63. South America Mepolizumab Sales Quantity by Type (2021-2026) & (Units)

Table 64. South America Mepolizumab Sales Quantity by Type (2027-2032) & (Units)

Table 65. South America Mepolizumab Sales Quantity by Application (2021-2026) & (Units)

Table 66. South America Mepolizumab Sales Quantity by Application (2027-2032) & (Units)

Table 67. South America Mepolizumab Sales Quantity by Country (2021-2026) & (Units)

Table 68. South America Mepolizumab Sales Quantity by Country (2027-2032) & (Units)

Table 69. South America Mepolizumab Consumption Value by Country (2021-2026) & (USD Million)

Table 70. South America Mepolizumab Consumption Value by Country (2027-2032) & (USD Million)

Table 71. Middle East & Africa Mepolizumab Sales Quantity by Type (2021-2026) & (Units)

Table 72. Middle East & Africa Mepolizumab Sales Quantity by Type (2027-2032) & (Units)

Table 73. Middle East & Africa Mepolizumab Sales Quantity by Application (2021-2026) & (Units)

Table 74. Middle East & Africa Mepolizumab Sales Quantity by Application (2027-2032) & (Units)

Table 75. Middle East & Africa Mepolizumab Sales Quantity by Country (2021-2026) & (Units)

Table 76. Middle East & Africa Mepolizumab Sales Quantity by Country (2027-2032) &

(Units)

Table 77. Middle East & Africa Mepolizumab Consumption Value by Country (2021-2026) & (USD Million)

Table 78. Middle East & Africa Mepolizumab Consumption Value by Country (2027-2032) & (USD Million)

Table 79. Mepolizumab Raw Material

Table 80. Key Manufacturers of Mepolizumab Raw Materials

Table 81. Mepolizumab Typical Distributors

Table 82. Mepolizumab Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. Mepolizumab Picture
- Figure 2. Global Mepolizumab Revenue by Type, (USD Million), 2021 & 2025 & 2032
- Figure 3. Global Mepolizumab Revenue Market Share by Type in 2025
- Figure 4. 100mg Pre-filled Syringe Examples
- Figure 5. 100mg Lyophilized Powder for Injection Examples
- Figure 6. Global Mepolizumab Revenue by Combination Therapy, (USD Million), 2021 & 2025 & 2032
- Figure 7. Global Mepolizumab Revenue Market Share by Combination Therapy in 2025
- Figure 8. Combination of Mepolizumab and Inhaled Corticosteroids Examples
- Figure 9. Combination of Mepolizumab and LABA Examples
- Figure 10. Global Mepolizumab Revenue by Route of Administration, (USD Million), 2021 & 2025 & 2032
- Figure 11. Global Mepolizumab Revenue Market Share by Route of Administration in 2025
- Figure 12. Subcutaneous Injection Examples
- Figure 13. Subcutaneous Infusion Examples
- Figure 14. Global Mepolizumab Revenue by Sales Channel, (USD Million), 2021 & 2025 & 2032
- Figure 15. Global Mepolizumab Revenue Market Share by Sales Channel in 2025
- Figure 16. Hospital Examples
- Figure 17. Retail Examples
- Figure 18. Online Examples
- Figure 19. Global Mepolizumab Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
- Figure 20. Global Mepolizumab Revenue Market Share by Application in 2025
- Figure 21. Severe Eosinophilic Asthma Examples
- Figure 22. Chronic Rhinosinusitis With Nasal Polyps Examples
- Figure 23. Eosinophilic Granulomatosis With Polyangiitis Examples
- Figure 24. Others Examples
- Figure 25. Global Mepolizumab Consumption Value, (USD Million): 2021 & 2025 & 2032
- Figure 26. Global Mepolizumab Consumption Value and Forecast (2021-2032) & (USD Million)
- Figure 27. Global Mepolizumab Sales Quantity (2021-2032) & (Units)
- Figure 28. Global Mepolizumab Price (2021-2032) & (US\$/Unit)

- Figure 29. Global Mepolizumab Sales Quantity Market Share by Manufacturer in 2025
- Figure 30. Global Mepolizumab Revenue Market Share by Manufacturer in 2025
- Figure 31. Producer Shipments of Mepolizumab by Manufacturer Sales (\$MM) and Market Share (%): 2025
- Figure 32. Top 3 Mepolizumab Manufacturer (Revenue) Market Share in 2025
- Figure 33. Top 6 Mepolizumab Manufacturer (Revenue) Market Share in 2025
- Figure 34. Global Mepolizumab Sales Quantity Market Share by Region (2021-2032)
- Figure 35. Global Mepolizumab Consumption Value Market Share by Region (2021-2032)
- Figure 36. North America Mepolizumab Consumption Value (2021-2032) & (USD Million)
- Figure 37. Europe Mepolizumab Consumption Value (2021-2032) & (USD Million)
- Figure 38. Asia-Pacific Mepolizumab Consumption Value (2021-2032) & (USD Million)
- Figure 39. South America Mepolizumab Consumption Value (2021-2032) & (USD Million)
- Figure 40. Middle East & Africa Mepolizumab Consumption Value (2021-2032) & (USD Million)
- Figure 41. Global Mepolizumab Sales Quantity Market Share by Type (2021-2032)
- Figure 42. Global Mepolizumab Consumption Value Market Share by Type (2021-2032)
- Figure 43. Global Mepolizumab Average Price by Type (2021-2032) & (US\$/Unit)
- Figure 44. Global Mepolizumab Sales Quantity Market Share by Application (2021-2032)
- Figure 45. Global Mepolizumab Revenue Market Share by Application (2021-2032)
- Figure 46. Global Mepolizumab Average Price by Application (2021-2032) & (US\$/Unit)
- Figure 47. North America Mepolizumab Sales Quantity Market Share by Type (2021-2032)
- Figure 48. North America Mepolizumab Sales Quantity Market Share by Application (2021-2032)
- Figure 49. North America Mepolizumab Sales Quantity Market Share by Country (2021-2032)
- Figure 50. North America Mepolizumab Consumption Value Market Share by Country (2021-2032)
- Figure 51. United States Mepolizumab Consumption Value (2021-2032) & (USD Million)
- Figure 52. Canada Mepolizumab Consumption Value (2021-2032) & (USD Million)
- Figure 53. Mexico Mepolizumab Consumption Value (2021-2032) & (USD Million)
- Figure 54. Europe Mepolizumab Sales Quantity Market Share by Type (2021-2032)
- Figure 55. Europe Mepolizumab Sales Quantity Market Share by Application (2021-2032)
- Figure 56. Europe Mepolizumab Sales Quantity Market Share by Country (2021-2032)

Figure 57. Europe Mepolizumab Consumption Value Market Share by Country (2021-2032)

Figure 58. Germany Mepolizumab Consumption Value (2021-2032) & (USD Million)

Figure 59. France Mepolizumab Consumption Value (2021-2032) & (USD Million)

Figure 60. United Kingdom Mepolizumab Consumption Value (2021-2032) & (USD Million)

Figure 61. Russia Mepolizumab Consumption Value (2021-2032) & (USD Million)

Figure 62. Italy Mepolizumab Consumption Value (2021-2032) & (USD Million)

Figure 63. Asia-Pacific Mepolizumab Sales Quantity Market Share by Type (2021-2032)

Figure 64. Asia-Pacific Mepolizumab Sales Quantity Market Share by Application (2021-2032)

Figure 65. Asia-Pacific Mepolizumab Sales Quantity Market Share by Region (2021-2032)

Figure 66. Asia-Pacific Mepolizumab Consumption Value Market Share by Region (2021-2032)

Figure 67. China Mepolizumab Consumption Value (2021-2032) & (USD Million)

Figure 68. Japan Mepolizumab Consumption Value (2021-2032) & (USD Million)

Figure 69. South Korea Mepolizumab Consumption Value (2021-2032) & (USD Million)

Figure 70. India Mepolizumab Consumption Value (2021-2032) & (USD Million)

Figure 71. Southeast Asia Mepolizumab Consumption Value (2021-2032) & (USD Million)

Figure 72. Australia Mepolizumab Consumption Value (2021-2032) & (USD Million)

Figure 73. South America Mepolizumab Sales Quantity Market Share by Type (2021-2032)

Figure 74. South America Mepolizumab Sales Quantity Market Share by Application (2021-2032)

Figure 75. South America Mepolizumab Sales Quantity Market Share by Country (2021-2032)

Figure 76. South America Mepolizumab Consumption Value Market Share by Country (2021-2032)

Figure 77. Brazil Mepolizumab Consumption Value (2021-2032) & (USD Million)

Figure 78. Argentina Mepolizumab Consumption Value (2021-2032) & (USD Million)

Figure 79. Middle East & Africa Mepolizumab Sales Quantity Market Share by Type (2021-2032)

Figure 80. Middle East & Africa Mepolizumab Sales Quantity Market Share by Application (2021-2032)

Figure 81. Middle East & Africa Mepolizumab Sales Quantity Market Share by Country (2021-2032)

Figure 82. Middle East & Africa Mepolizumab Consumption Value Market Share by

Country (2021-2032)

Figure 83. Turkey Mepolizumab Consumption Value (2021-2032) & (USD Million)

Figure 84. Egypt Mepolizumab Consumption Value (2021-2032) & (USD Million)

Figure 85. Saudi Arabia Mepolizumab Consumption Value (2021-2032) & (USD Million)

Figure 86. South Africa Mepolizumab Consumption Value (2021-2032) & (USD Million)

Figure 87. Mepolizumab Market Drivers

Figure 88. Mepolizumab Market Restraints

Figure 89. Mepolizumab Market Trends

Figure 90. Porters Five Forces Analysis

Figure 91. Manufacturing Cost Structure Analysis of Mepolizumab in 2025

Figure 92. Manufacturing Process Analysis of Mepolizumab

Figure 93. Mepolizumab Industrial Chain

Figure 94. Sales Channel: Direct to End-User vs Distributors

Figure 95. Direct Channel Pros & Cons

Figure 96. Indirect Channel Pros & Cons

Figure 97. Methodology

Figure 98. Research Process and Data Source

I would like to order

Product name: Global Mepolizumab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/GAEA90BCE724EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GAEA90BCE724EN.html>